An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger)

作者：Agulnik M^*; Yarber J L; Okuno S H; von Mehren M; Jovanovic B D; Brockstein B E; Evens A M; Benjamin R S

来源：Annals of Oncology, 2013, 24(1): 257-263.

DOI：10.1093/annonc/mds237

• angiosarcoma
• bevacizumab
• hemangioendotheliomas
• soft tissue sarcoma

To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. %26lt;br%26gt;In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of %26lt; 1, adequate organ function and had not received any radiation treatment in the last 28 days. %26lt;br%26gt;Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. %26lt;br%26gt;Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.

• 出版日期2013-1
• 单位西北大学